This is a proposed randomized prospective study to evaluate both the anti-inflammatory and analgesic effects of a COX-2 inhibitor, celecoxib, in patients with aspirin-exacerbated respiratory disease and Chronic rhinosinusitis following endoscopic sinus surgery. The investigators hypothesize that supplementation with celecoxib can potentially improve surgical outcomes and reduce the postoperative usage of opioid analgesics without an increased risk of bleeding or asthma exacerbation
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Post FESS changes in the Lund-Kennedy Endoscopic Score (LKES)
Timeframe: 1 week and 4 weeks post-operatively.
Post FESS changes in the Peri-Operative Sinus Endoscopy (POSE) score
Timeframe: 1 week and 4 weeks post-operatively.
Post FESS changes in the validated Sino-Nasal Outcome Test 22 (SNOT-22) questionnaire
Timeframe: 1 week and 4 weeks post-operatively.